SYK
Tyrosine-protein kinase SYK
As of the edition of 20 October 2026, SYK (tyrosine-protein kinase SYK, UniProt P43405) has 11 drugs tested at it and 15 companies on the list, 9 on route A and 3 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P43405
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 93
- Disease areas
- Immune system; Blood and lymph; Cancer; Skin and connective tissue; Bones, joints and muscles; Lungs and airways; Inherited and neonatal; Pregnancy and women's health
- Registered trials of its drugs
- 122
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Active | 2 |
| Went quiet | 2 |
| Stopped | 6 |
| Total | 11 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Fostamatinib | Marketed | Phase 3 | Ends 2031 |
| Mivavotinib | Stopped | Phase 2 | none listed |
| Entospletinib | Stopped | Phase 3 | none listed |
| Sovleplenib | Stopped | Phase 3 | none listed |
| Gusacitinib | Stopped | Phase 2 | none listed |
| Lanraplenib | Stopped | Phase 2 | none listed |
| GSK2646264 | Went quiet | Phase 1 | none listed |
| R788 | Active | Phase 3 | none listed |
| TQB3473 | Active | Phase 2 | none listed |
| GS-9876 | Went quiet | Phase 2 | none listed |
| PRT-2607 | Stopped | Phase 2 | none listed |
11 of 11 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 9 |
| Route B | 3 |
| Engaged | 2 |
| Undetermined | 1 |
| Total on the list | 15 |
| Company | Route |
|---|---|
| Hutchmed | Route A |
| Rigel Pharmaceuticals | Route B |
| Gilead Sciences | Route A |
The other 12 companies at SYK
In the product15 companies in all; 12 are not named here, and no score is.
See the 15 companies at SYK, ranked, with the facts behind eachRequest access. Nothing is shown until you do.